Pharmacologic Management of Duchenne Muscular Dystrophy: Target Identification and Preclinical Trials

Abstract excerpt

Duchenne muscular dystrophy (DMD) is an X-linked human disorder in which absence of the protein dystrophin causes degeneration of skeletal and cardiac muscle. For the sake of treatment development, over and above definitive genetic and cell-based therapies, there is considerable interest in drugs that target downstream disease mechanisms. Drug candidates have typically been chosen based on the nature of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Muscle Physiology and Disorders
• Share to Tissue Engineering and Regenerative Medicine
• Share to Virus-based gene therapy research